Business ❯ Pharmaceutical Industry ❯ Market Competition

Pricing Strategies

Generic Drugs Direct-to-Consumer Sales Novo Nordisk Generic Medications Consumer Access Eli Lilly GLP-1 Drugs Consumer Impact Regulatory Actions Copycat Drugs Investor Relations Compounded Drugs Drug Development Eli Lilly and Novo Nordisk Supply Chain Management Pharmacy Benefit Managers Cost Reduction Patient Access Novo Nordisk and Eli Lilly Vaccine and Drug Development Consumer Discounts CVS Health Market Access Ozivy Semaglutide Executive Orders Generic Drug Launches EMS Product Development Subscription Models Product Launches Biosimilar Pricing

FDA Approves Langlara as Interchangeable Biosimilar to Lantus

Pharmacy-level substitution could expand access.

Novo Nordisk to Cut U.S. List Prices for Wegovy, Ozempic and Rybelsus to $675 in 2027

Indiana Sues Eli Lilly, Alleging Scheme to Inflate Insulin Prices

Lilly Cuts Zepbound Cash Prices on LillyDirect as GLP‑1 Price Competition Deepens